Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 67

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 67
---
 the People & Compensation Committee recommended to the board of the Company that the Compensation Discussion and Analysis be included in this proxy statement. The People & Compensation Committee of
the Board of Directors of Pacira BioSciences, Inc.

| ​ | Michael YangChair | ​ | ​ | Abraham Ceesay | ​ | ​ | Mark Kronenfeld | ​ |

The People & Compensation Committee consists solely of these three independent directors. No member of the People & Compensation Committee is a current or former officer or employee of the Company or any of its subsidiaries, and in 2024, none of our executive officers served on the board of directors or compensation committee of any other entity whose directors or executive officers served on the Company’s board or People & Compensation Committee.

76 | investor.pacira.com

TABLE OF CONTENTS Executive Compensation Compensation Tables Compensation Tables—Contents

| ​ | 77 | ​ | ​ | COMPENSATION TABLES                                | ​ |
| ​ | 77 | ​ | ​ | Summary Compensation Table                         | ​ |
| ​ | 78 | ​ | ​ | Grants of Plan-Based Awards Table                  | ​ |
| ​ | 79 | ​ | ​ | Outstanding Equity Awards at Fiscal Year-End Table | ​ |
| ​ | 81 | ​ | ​ | Option Exercises and Stock Vested Table            | ​ |

| ​ | 81 | ​ | ​ | Non-Qualified Deferred Compensation Plan                             | ​ |
| ​ | 83 | ​ | ​ | Employment Agreements, Severance, and Change of Control Arrangements | ​ |
| ​ | 85 | ​ | ​ | Potential Payments Upon Termination or Change of Control             | ​ |

SUMMARY COMPENSATION TABLE The following table sets forth information regarding compensation earned for services rendered during fiscal years 2024, 2023, and 2022 for our chief executive officer, our chief financial officer, and the three other most highly compensated executive officers who were serving as executive officers at the end of 2024. We refer to these individuals as our “named executive officers.”

| Name and                                                        
 Principal Position                                              | ​ | ​ | Year |   |      |   | ​ | ​ | Salary($) |   |         |   | ​ | ​ | Bonus(1)($) |   |         |   | ​ | ​ | StockAwards(2)($) |   |           |   | ​ | ​ | OptionAwards(2)($) |   |           |   | ​ | ​ | Non